Generation and persistence of S1 IgG and neutralizing antibodies in post-COVID-19 patients

[1] Thevarajan I(2020)Clinical presentation and management of COVID-19 Med J Aust 213 134-139

[2] Buising KL(2020)Antibody response to SARS-CoV-2 infection in humans: a systematic review PLoS ONE 15 1-27

[3] Cowie BC(2020)Structural proteins in severe acute respiratory syndrome coronavirus-2 Arch Med Res 51 482-491

[4] Post N(2020)Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor Nat Commun 11 4541-1149

[5] Eddy D(2020)Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 Acta Pharmacol Sin 41 1141-124

[6] Huntley C(2020)A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 Nature 584 120-1042

[7] van Schalkwyk MCI(2020)Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology Cell 183 1024-456

[8] Shrotri M(2020)Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike Nature 584 450-1854

[9] Leeman D(2020)Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial Lancet 395 1845-1084

[10] Satarker S(2021)Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study Lancet 397 1075-6

[1] Thevarajan I(2020)Clinical presentation and management of COVID-19 Med J Aust 213 134-139

[2] Buising KL(2020)Antibody response to SARS-CoV-2 infection in humans: a systematic review PLoS ONE 15 1-27

[3] Cowie BC(2020)Structural proteins in severe acute respiratory syndrome coronavirus-2 Arch Med Res 51 482-491

[4] Post N(2020)Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor Nat Commun 11 4541-1149

[5] Eddy D(2020)Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 Acta Pharmacol Sin 41 1141-124

[6] Huntley C(2020)A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 Nature 584 120-1042

[7] van Schalkwyk MCI(2020)Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology Cell 183 1024-456

[8] Shrotri M(2020)Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike Nature 584 450-1854

[9] Leeman D(2020)Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial Lancet 395 1845-1084

[10] Satarker S(2021)Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study Lancet 397 1075-6